Novartis Gets FDA Approval for Prostate-Cancer Treatment
24 Marzo 2022 - 12:59AM
Noticias Dow Jones
By Cecilia Butini
Novartis AG said late Wednesday that the U.S. Food and Drug
Administration has given its prostate-cancer treatment, Pluvicto,
the green light, and it is now expected to become available within
weeks.
The Swiss pharma company said that Pluvicto works against a
certain type of advanced prostate cancer.
The FDA approval is based on the result of a Phase 3 trial which
showed that patients treated with the drug, plus the standard
available treatment, had a 38% reduction in the risk of death,
Novartis said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 24, 2022 02:44 ET (06:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024